Associated Papers
GenoStaR: An R Package for Genotype to Star Allele Conversion for Major Cytochrome P450 Family of Genes.
Coulter AJ et al.
Clinical Pharmacology and Therapeutics, 2026
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
CYP1A2 expression and activity in a large panel of human nonneoplastic surgical liver samples: Influence of genetics, lifestyle, and other factors.
Kuhn UD et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2025
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
A review of the existing literature on buprenorphine pharmacogenomics.
Meaden CW et al.
The Pharmacogenomics Journal, 2021
In silico screening and analysis of nonsynonymous SNPs in human CYP1A2 to assess possible associations with pathogenicity and cancer susceptibility.
Navapour L et al.
Scientific Reports, 2021
Impact of peripheral mutations on the access channels of human cytochrome P450 1A2.
Ying B et al.
Journal of Biomolecular Structure & Dynamics, 2020
Pharmacogene Variation in Thai Plasmodium vivax Relapse Patients Treated with a Combination of Primaquine and Chloroquine.
Chamnanphon M et al.
Pharmacogenomics and Personalized Medicine, 2020
An optimized prediction framework to assess the functional impact of pharmacogenetic variants.
Zhou Y et al.
The Pharmacogenomics Journal, 2019
Pharmacogenetic analysis of opioid dependence treatment dose and dropout rate.
Crist RC et al.
The American Journal of Drug and Alcohol Abuse, 2018
Palpitations and Asthenia Associated with Venlafaxine in a CYP2D6 Poor Metabolizer and CYP2C19 Intermediate Metabolizer.
Garcia S et al.
Case Reports in Genetics, 2017
Impaired dacarbazine activation and 7-ethoxyresorufin deethylation in vitro by polymorphic variants of CYP1A1 and CYP1A2: implications for cancer therapy.
Lewis BC et al.
Pharmacogenetics and Genomics, 2016
Prediction of three-dimensional structures and structural flexibilities of wild-type and mutant cytochrome P450 1A2 using molecular dynamics simulations.
Watanabe Y et al.
Journal of Molecular Graphics & Modelling, 2016
Use of combinatorial pharmacogenomic testing in two cases from community psychiatry.
Fields ES et al.
Pharmacogenomics and Personalized Medicine, 2016
Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
Altar CA et al.
The Pharmacogenomics Journal, 2015
Functional characterization of 20 allelic variants of CYP1A2.
Ito M et al.
Drug Metabolism and Pharmacokinetics, 2015
A theoretical study on the mechanism of a superficial mutation inhibiting the enzymatic activity of CYP1A2.
Ma LN et al.
Interdisciplinary Sciences, Computational Life Sciences, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Long-range effects of a peripheral mutation on the enzymatic activity of cytochrome P450 1A2.
Zhang T et al.
Journal of Chemical Information and Modeling, 2011
Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression.
Palma BB et al.
The Pharmacogenomics Journal, 2010
Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Zhou SF et al.
Drug Metabolism Reviews, 2010
Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.
Zhou SF et al.
The Aaps Journal, 2009
The loci of evolution: how predictable is genetic evolution?
Stern DL et al.
Evolution; International Journal of Organic Evolution, 2008
CYP1A2 F21L and F186L polymorphisms in an Italian population sample.
Pucci L et al.
Drug Metabolism and Pharmacokinetics, 2007
Functional analysis of three CYP1A2 variants found in a Japanese population.
Saito Y et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2005
Six novel nonsynonymous CYP1A2 gene polymorphisms: catalytic activities of the naturally occurring variant enzymes.
Murayama N et al.
The Journal of Pharmacology and Experimental Therapeutics, 2004